abvacc
AbVacc is a Rockville, Maryland biotech spun off from Integrated BioTherapeutics in 2023 that develops structure-guided vaccines and engineered antibody therapeutics for emerging infectious diseases, funded via government grants and licensed to pharma partners for clinical development.
- Company typePrivate
- Founded2008
- HeadquartersRockville, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What abvacc does
AbVacc is a Rockville, Maryland-based biotechnology company spun off from Integrated BioTherapeutics in January 2023 to focus on structure-guided rational design of vaccines and antibody therapeutics for emerging infectious diseases. Its pipeline spans five viral targets (Ebola, Marburg, Nipah, Influenza, and broader filoviruses) and three bacterial targets (Staphylococcus aureus, Clostridium difficile, and Bacillus anthracis), supported by three proprietary platform technologies: ISTAb (Infection Site Targeted Antitoxin Antibody) for bacterial targets, InstaVax, and a Smart Immunogens/Smart Probes discovery engine that interrogates immune repertoires to identify rare protective antibodies.
The technology portfolio includes monoclonal antibody candidates (IBT-T02 pan-ebolavirus, ABV-103 anti-Marburg, pan-influenza A, ABV-104 S. aureus cocktail), engineered ISTAb antibodies against C. difficile and B. anthracis, and vaccines including the rationally designed multivalent S. aureus toxoid (IBT-V02/LBT-SA7), a recombinant VSV-based Nipah vaccine with UTMB, and a pan-filovirus vaccine. Lead candidates have demonstrated full protection against lethal viral challenge in nonhuman primates, ferrets, guinea pigs, and mice, with ABV-103 currently at the IND-enabling stage under a $16.3M NIAID contract and LBT-SA7 advancing through Phase 1 under LimmaTech Biologics.
AbVacc is preclinical/early-clinical and generates cash primarily through non-dilutive government grants (NIAID, CARB-X, NIH), strategic equity from Novo Holdings' REPAIR Impact Fund, and licensing/co-development partnerships with pharmaceutical companies such as LimmaTech Biologics (S. aureus vaccine), Blue Water Vaccines (monkeypox/Marburg VLP programs), and Emery Pharma (intranas
abvacc firmographics
Firmographics- Name
- abvacc
- Legal name
- AbVacc, Inc.
- Website
- https://abvacc.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- AbVacc is a Rockville, Maryland biotech spun off from Integrated BioTherapeutics in 2023 that develops structure-guided vaccines and engineered antibody therapeutics for emerging infectious diseases, funded via government grants and licensed to pharma partners for clinical development.
- Ownership category
- akta.pro rank
abvacc industry classification
Industry- Product category
- Biotechnology — Vaccines and Antibody Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF)
- akta.pro secondary industries
- Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
Keywords
Where abvacc is headquartered
LocationHeadquarters
- HQ city
- Rockville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
abvacc business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Licensing and Co-development: AbVacc develops pipeline candidates through preclinical and early clinical stages, then licenses to larger pharmaceutical partners for late-stage development and commercialization. Revenue comes from licensing fees, milestone payments, and potential royalties.
- Government Contracts and Grants: Non-dilutive funding from government agencies (NIAID, CARB-X, NIH) for development of vaccines and therapeutics targeting infectious diseases and biodefense threats
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
abvacc product offering
Product offeringCore offering
AbVacc is a biotechnology company developing rationally designed vaccines and engineered monoclonal antibody therapeutics for emerging infectious diseases and biodefense threats. Its pipeline targets five viral pathogens (Ebola, Marburg, Nipah, influenza, and other filoviruses) and three bacterial pathogens (S. aureus, C. difficile, B. anthracis) using structure-guided design. The company advances candidates through preclinical and IND-enabling stages and licenses them to larger pharmaceutical partners for late-stage clinical development and commercialization.
Product overview
AbVacc is a biotechnology company developing rationally designed vaccines and engineered antibody therapeutics for emerging infectious diseases. The company's portfolio includes two main platform technologies (ISTAb and InstaVax) that enable development of targeted antibody and vaccine products. The antibody therapeutic pipeline includes IBT-T02 (Pan-Ebolavirus), ABV-103 (Anti-Marburg), ABV-104 (S. aureus), Cd-ISTAb (C. difficile), Ba-ISTAb (B. anthracis), and an Influenza monoclonal antibody. The vaccine pipeline includes IBT-V02/LBT-SA7 (S. aureus toxoid vaccine), Nipah virus vaccine, and Filovirus vaccine. The company operates from Rockville, Maryland, with a focus on structure-guided design of immunogens.
Differentiator
Problem solved
Functional benefit
Products and services
- IBT-T02 (Pan-Ebolavirus Therapeutic) A cocktail of two monoclonal antibodies with potent neutralizing activity against Ebola, Sudan, and Bundibugyo viruses. IBT-T02 has provided full protection against lethal challenge with these viruses in nonhuman primates, ferrets, guinea pigs, and mice, and is currently at the IND-enabling stage. Targeted at biodefense and pandemic preparedness stakeholders for emerging viral threats.
- ABV-103 (Anti-Marburg Virus Disease Therapeutic) A humanized macaque-derived monoclonal antibody (also referenced as IBT-T03H) with potent and broad neutralizing activity toward all strains of Marburg and Ravn viruses, with protection demonstrated in animal models including gold standard nonhuman primates. Currently at the IND-enabling stage under a NIAID-funded program supporting formulation, process, and Phase 1 development.
- Influenza Monoclonal Antibody A pan-influenza A monoclonal antibody developed in collaboration with Abviro, LLC with broad heterosubtypic effective treatment for both Group 1 and Group 2 influenza A viruses without inducing virus resistance. Aimed at addressing limitations of current influenza antivirals and seasonal vaccine approaches.
- ABV-104 (S. aureus Monoclonal Antibody Cocktail) Cocktail of highly potent antibodies against key toxins, superantigens, and virulence factors of Staphylococcus aureus. Being evaluated against several life-threatening syndromes of S. aureus infections in collaboration with Eliteimmune, Inc., addressing the growing antimicrobial resistance burden in invasive Staph infections.
- Cd-ISTAb (C. difficile ISTAb) Neutralizing antibody cocktail against TcdB engineered using Infection Site Targeted Antitoxin Antibody (ISTAb) technology to target the surface of C. difficile and achieve both toxin neutralization and opsonophagocytic bacterial clearance for treatment of C. difficile infection (CDI).
- Ba-ISTAb (B. anthracis ISTAb) Anti-protective antigen (PA) neutralizing antibody targeted to the surface of B. anthracis using ISTAb technology, achieving both toxin neutralization and bacterial clearance for treatment of Inhalation Anthrax, a high-priority biodefense indication.
- IBT-V02 / LBT-SA7 (S. aureus Toxoid Vaccine) Rationally designed multivalent toxoid vaccine (originally 5-component as IBT-V02, expanded to 6-component as LBT-SA7) against pore-forming toxins and superantigens of Staphylococcus aureus for prevention of S. aureus skin and skin structure infections (SSSI). Positioned as the only entirely toxoid vaccine for S. aureus under development. Licensed to LimmaTech Biologics for Phase 1 clinical development, with option to acquire full worldwide rights.
- Nipah Virus Vaccine Recombinant vesicular stomatitis virus (VSV)-based vaccine against Nipah virus (NiV) developed in collaboration with the University of Texas Medical Branch (UTMB). Preclinical work showed single-dose protection against NiV Bangladesh strain in rodent models, targeting a pathogen with reported human case fatality rates as high as 60-100%.
- Filovirus Vaccine Pan-filovirus vaccine using structure-based rational design against hemorrhagic fevers caused by Ebola, Sudan, Bundibugyo, and Marburg viruses. Leverages broadly neutralizing antibodies against the filovirus glycoprotein identified by AbVacc and collaborators, with protection demonstrated in rodent and nonhuman primate models.
Quantifiable outcome
- IBT-T02 provided full protection against lethal challenge with Ebola, Sudan, and Bundibugyo viruses in nonhuman primates, ferrets, guinea pigs, and mice
- +2 more outcomes
Companies that use abvacc
Customer profileSegments3 records
Ideal customer profiles2 records
abvacc technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
abvacc partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered minor and core.
- Emery PharmaminorStrategic collaboration to develop super fast-acting intranasal naloxone for rapid reversal of opioid overdoses. AbVacc contributes pharmacokinetic modeling expertise; Emery Pharma provides pharmaceutical development and regulatory compliance capabilities.
- LimmaTech BiologicscoreLimmaTech received exclusive clinical development license for AbVacc's multivalent toxoid vaccine candidate (LBT-SA7/IBT-V02) against Staphylococcus aureus. LimmaTech has option to acquire full worldwide rights after Phase 1 trial readout.
- Blue Water VaccinescoreJoint development of vaccine candidates targeting monkeypox and Marburg virus disease. AbVacc contributes expertise in MVD and rational antigen design; Blue Water Vaccines provides norovirus shell and protrusion (S&P) virus-like particle (VLP) platform.
- Scripps Research InstitutecoreScientific collaboration for structure-based vaccine design and antibody discovery. Collaborators on filovirus vaccine development.
- University of Texas Medical Branch (UTMB)coreCollaboration for development of recombinant VSV-based vaccine against Nipah virus. UTMB provides expertise in filovirus and Nipah virus research.
- Johns Hopkins UniversitycoreAcademic collaboration for vaccine and immunotherapeutics development targeting infectious diseases.
- La Jolla Institute for ImmunologycoreScientific collaboration for structure-based vaccine design. Collaborators on filovirus vaccine development.
- Eliteimmune Corp.coreCollaboration for development of S. aureus monoclonal antibody cocktail (ABV-104). Joint product development for antibodies against key toxins and virulence factors.
- ViroVax LLCcoreStrategic partnership for vaccine development and immunotherapeutics.
- USAMRIID (U.S. Army Medical Research Institute of Infectious Diseases)coreCollaboration with U.S. Government agency for biodefense research and development of vaccines and therapeutics for emerging infectious diseases.
- NEIDL (National Emerging Infectious Diseases Laboratories)minorCollaboration for research on emerging infectious diseases.
- Washington UniversitycoreAcademic collaboration for vaccine and immunotherapeutics development.
- University of MarylandcoreAcademic collaboration for vaccine and immunotherapeutics development.
- University of RochestercoreAcademic collaboration for vaccine and immunotherapeutics development.
- UCLAcoreAcademic collaboration for vaccine and immunotherapeutics development.
- Mapp BiopharmaceuticalminorCollaboration for development of vaccines and immunotherapeutics for infectious diseases.
- Integral MolecularcoreCollaboration to engineer broadly protective ebolavirus vaccines using Integral Molecular's GeneCanvas protein engineering platform combined with IBT's neutralizing Ebola antibodies.
- Abviro LLCcoreCollaboration for development of pan-influenza A monoclonal antibody with broad heterosubtypic effectiveness against both Group 1 and 2 influenza A viruses.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
abvacc competitors and assessment
Company assessmentEmerging players
- Abviro: Co-developer with AbVacc of pan-influenza A monoclonal antibody. Directly comparable as an emerging infectious disease antibody developer and active AbVacc collaboration partner.
- Eligo Bioscience: Developer of engineered phage and biological therapeutics targeting bacterial pathogens including S. aureus. Comparable as an emerging anti-infective biotech focused on AMR, an overlapping indication space with AbVacc.
- SAB Biotherapeutics: Developer of polyclonal antibody therapeutics (SAB-185 for Ebola, etc.) using a transchromosomic platform. Comparable as an emerging infectious disease antibody developer targeting biodefense indications.
Broad incumbents
- BioNTech: mRNA-based infectious disease vaccine developer with pandemic preparedness programs. Broad incumbent pursuing analogous vaccine targets via a different technology platform.
- Moderna: mRNA platform developer with active infectious disease vaccine programs including Ebola and other pandemic preparedness targets. Broad incumbent in the same vaccine/biodefense category as AbVacc.
- Regeneron Pharmaceuticals: Approved REGN-EB3 antibody cocktail for Ebola and runs broad antibody discovery (VelociSuite) platform. Comparable as a large incumbent developing antibody therapeutics for infectious diseases including filoviruses.
Direct peers
- Mapp Biopharmaceutical: Developer of MBP134 (now Inmazeb/Ansuvimab approved for Ebola) and other filovirus antibody therapeutics. Directly comparable as an infectious disease antibody developer targeting the same Ebola/Marburg pathogens AbVacc pursues.
- LimmaTech Biologics: Licensee of AbVacc's LBT-SA7 S. aureus vaccine and clinical developer. Directly comparable as a developer of S. aureus vaccines and anti-infective biologics; also a strategic partner of AbVacc.
- Blue Water Vaccines: Co-developer with AbVacc on monkeypox and Marburg VLP-based vaccine candidates using norovirus S&P VLP platform. Directly comparable as an early-stage infectious disease vaccine developer and active AbVacc partner.
Others
- Integral Molecular: Antibody discovery and protein engineering partner of AbVacc for broadly protective ebolavirus vaccines using GeneCanvas platform. Comparable as an enabling technology peer in the same ebolavirus vaccine development program.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
abvacc social profiles
Digital presenceabvacc financial estimates
Financial estimateRevenue estimate
Valuation estimate
abvacc leadership team
Management profileNumber of profiles
Profiles4 records
abvacc funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
abvacc M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about abvacc
What does abvacc do?
AbVacc is a biotechnology company developing rationally designed vaccines and engineered monoclonal antibody therapeutics for emerging infectious diseases and biodefense threats. Its pipeline targets five viral pathogens (Ebola, Marburg, Nipah, influenza, and other filoviruses) and three bacterial pathogens (S. aureus, C. difficile, B. anthracis) using structure-guided design. The company advances candidates through preclinical and IND-enabling stages and licenses them to larger pharmaceutical partners for late-stage clinical development and commercialization.
Is abvacc a public or private company?
abvacc is a private company. It is classified as venture growth investor backed and is currently operating.
When was abvacc founded?
abvacc was founded in 2008. It employs 1 to 10 people.
Where is abvacc based?
abvacc is headquartered in Rockville, United States, in the North America region.
How does abvacc make money?
Two revenue lines are on record. Licensing and Co-development is the primary driver. The others are government Contracts and Grants.
Who are abvacc's main competitors?
Emerging players on record are Abviro, Eligo Bioscience and SAB Biotherapeutics. Broad incumbents are BioNTech, Moderna and Regeneron Pharmaceuticals. Direct peers are Mapp Biopharmaceutical, LimmaTech Biologics and Blue Water Vaccines. Integral Molecular is listed as an others.
Does abvacc have an API?
No public API is recorded for abvacc.
What industry is abvacc in?
abvacc's product category is Biotechnology — Vaccines and Antibody Therapeutics. Its primary akta.pro industry code is HLAIAEAF, Pandemic Preparedness & Rapid-Response Vaccines, with a secondary code of HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens). Its NAICS code is 325414 and its SIC code is 2836.